甲氨蝶呤在初治早期类风湿关节炎中剂量反应关系的Meta回归分析
结果显示,在MTX单药、联合生物DMARD或糖皮质激素治疗中,较高的初始MTX剂量均未带来更好的临床结局,效应量均较小。
要点
- 在DMARD初治早期RA中,MTX单药治疗增加剂量并未显示更高疗效。
- MTX联合糖皮质激素时,较高MTX剂量与较差的HAQ结局相关,但与DAS/DAS28或ESR/CRP无关。
- MTX联合生物DMARD时,较高剂量与较差的HAQ和DAS/DAS28相关,效应量均小。
核心结论
- 在DMARD初治早期RA患者中,无论MTX单药还是联合生物DMARD或糖皮质激素,较高的初始MTX剂量均与更好的临床结局无关。
- 短期来看,起始高剂量MTX相比低剂量带来的获益很小。
研究设计与样本
- 系统文献检索纳入早期、DMARD初治、接受MTX治疗的RA试验和队列,要求有治疗开始6个月内的临床结果数据。
- 计算HAQ、ESR/CRP和DAS/DAS28的Cohen效应量,并对每个结局进行随机效应Meta回归分析,以治疗组为预测因子,校正基线HAQ或疾病活动度和评估时间点。
主要发现
- Meta回归不支持MTX单药治疗中增加剂量具有更高有效性。
- 联合合成DMARD的治疗组数量太少,无法进行Meta回归分析。
- 联合糖皮质激素时,较高MTX剂量与较高(较差)的HAQ结局相关,但与DAS/DAS28或ESR/CRP无关。
- 联合生物DMARD时,较高MTX剂量与较高(较差)的HAQ和DAS/DAS28相关,但与ESR/CRP无关。
- 所有效应量均较小。
临床怎么用
- 对于DMARD初治早期RA患者,起始MTX治疗时无需追求高剂量,低剂量起始的短期临床获益与高剂量相当。
局限性
- 联合合成DMARD的治疗组数量太少,无法进行Meta回归分析。
- 所有观察到的效应量均较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate a possible short-term dose-response relationship of initial treatment with methotrexate (MTX) in monotherapy and combination therapy in recent-onset rheumatoid arthritis (RA) patients. METHODS: A systematic literature search was performed on trials and cohorts, including early, disease-modifying antirheumatic drug (DMARD)-naive RA patients treated with MTX, with data on clinical results within 6 months from treatment start. Cohen's effect sizes were calculated for the Health Assessment Questionnaire (HAQ), erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP) level, and/or Disease Activity Score (DAS)/in 28 joints (DAS28) in 4 treatment groups: MTX monotherapy, or MTX in combination with synthetic (cs) DMARDs, biologic (b) DMARDs, or glucocorticoids. Random-effects meta-regression analyses were performed for each outcome, with treatment group as the predictor corrected for baseline HAQ or disease activity and assessment point. RESULTS: Thirty-one studies including 5,589 patients were included. The meta-regression did not support higher effectiveness of increasing MTX dose in monotherapy. The number of treatment groups using combination therapy with csDMARDs was too small to perform meta-regression analyses. In combination therapy with glucocorticoids, a higher MTX dose was associated with higher (worse) outcome HAQ, but not with DAS/DAS28 or ESR/CRP level. In combination therapy with bDMARDs, a higher MTX dose was associated with higher outcome HAQ and DAS/DAS28, but not with ESR/CRP level. All effect sizes were small. CONCLUSION: In DMARD-naive, early RA patients who start MTX, either as monotherapy or in combination with bDMARDs or glucocorticoids, a higher initial dose of MTX was not associated with better clinical outcomes. This finding suggests that there is little short-term gain from starting with high compared to low MTX doses.
引用
- Bergstra SA, Allaart CF, Stijnen T, et al. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients. Arthritis Care Res (Hoboken). 2017. PMID: 27992656. doi:10.1002/acr.23164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。